Amedisys, Inc. (NASDAQ:AMED) Short Interest Update

Amedisys, Inc. (NASDAQ:AMED) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,790,000 shares, an increase of 18.5% from the September 15th total of 1,510,000 shares. Based on an average daily volume of 384,000 shares, the short-interest ratio is presently 4.7 days. Approximately 5.6% of the shares of the company are sold short.

Institutional Investors Weigh In On Amedisys

Large investors have recently bought and sold shares of the business. Banque Cantonale Vaudoise purchased a new position in shares of Amedisys in the 1st quarter worth $60,000. Innealta Capital LLC bought a new stake in Amedisys during the second quarter worth approximately $64,000. Covestor Ltd raised its position in Amedisys by 134.2% during the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after purchasing an additional 447 shares during the period. Signaturefd LLC lifted its stake in shares of Amedisys by 88.2% in the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after purchasing an additional 530 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of Amedisys by 14.5% in the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock worth $211,000 after purchasing an additional 277 shares during the period. Institutional investors own 94.36% of the company’s stock.

Amedisys Stock Up 0.5 %

Shares of AMED stock opened at $96.81 on Tuesday. The company’s fifty day simple moving average is $97.25 and its two-hundred day simple moving average is $95.27. Amedisys has a 52 week low of $89.55 and a 52 week high of $98.95. The stock has a market cap of $3.16 billion, a P/E ratio of -151.27, a PEG ratio of 1.89 and a beta of 0.78. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.10. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. The company had revenue of $591.19 million during the quarter, compared to analyst estimates of $579.34 million. Analysts predict that Amedisys will post 4.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Deutsche Bank Aktiengesellschaft downgraded shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target on the stock. in a research report on Monday, July 29th. William Blair cut shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $101.00 target price on shares of Amedisys in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Amedisys currently has an average rating of “Hold” and an average price target of $100.67.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.